TARSUS PHARMACEUTICALS, INC. (TARS) Spending and interest coverage
- R&D / revenue · 12 months: Value 14.46%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.55%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 14.46% | Research and development expense / revenue. Period ending 2026-06-30. $87.68M ÷ $606.33M × 100 ≈ 14.46% |
| Stock-based compensation / revenue · 12 months | 8.55% | Share-based compensation / revenue. Period ending 2026-06-30. $51.81M ÷ $606.33M × 100 ≈ 8.55% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 87.68M USD | Research and Development Expense |
| Revenue | 606.33M USD | |
| Stock-based compensation | 51.81M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -48.53M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $87.68M | $606.33M | $51.81M | $-48.53M | (m) | 14.46% | 8.55% | (m) | (m) |
| 2026-03-31 | $72.26M | $535.08M | $46.76M | $-50.81M | (m) | 13.51% | 8.74% | (m) | (m) |
| 2025-12-31 | $64.32M | $451.36M | $41.72M | $-70.97M | (m) | 14.25% | 9.24% | (m) | (m) |
| 2025-09-30 | $63.16M | $366.10M | $34.81M | $-87.41M | (m) | 17.25% | 9.51% | (m) | (m) |
| 2025-06-30 | $59.00M | $295.52M | $29.98M | $-98.05M | (m) | 19.97% | 10.15% | (m) | (m) |
| 2025-03-31 | $55.73M | $233.67M | $29.23M | $-109.17M | (m) | 23.85% | 12.51% | (m) | (m) |
| 2024-12-31 | $53.39M | $182.95M | $27.82M | $-120.57M | (m) | 29.18% | 15.20% | (m) | (m) |
| 2024-09-30 | $49.82M | $129.62M | $25.90M | $-140.60M | (m) | 38.43% | 19.98% | (m) | (m) |
| 2024-06-30 | $49.80M | $83.37M | $23.73M | $-156.37M | (m) | 59.72% | 28.46% | (m) | (m) |
| 2024-03-31 | $50.02M | $42.56M | $21.44M | $-155.89M | $3.65M | 117.53% | 50.38% | -42.77× | Reported |
| 2023-12-31 | $50.31M | $17.45M | $19.83M | $-143.16M | $3.35M | 288.37% | 113.66% | -42.78× | Reported |
| 2023-09-30 | $47.03M | $14.37M | $18.02M | $-113.77M | $3.05M | 327.29% | 125.38% | -37.31× | Reported |
| 2023-06-30 | $45.84M | (m) | $16.35M | $-95.74M | $2.82M | (m) | (m) | -33.90× | Reported |
| 2023-03-31 | $42.90M | (m) | $14.69M | $-68.14M | $2.57M | (m) | (m) | -26.55× | Reported |
| 2022-12-31 | $42.62M | $25.82M | $13.46M | $-62.71M | $2.20M | 165.11% | 52.14% | -28.52× | Reported |
| 2022-09-30 | $40.63M | $16.15M | $11.97M | $-62.10M | (m) | 251.54% | 74.09% | (m) | (m) |
| 2022-06-30 | $39.93M | $17.39M | $10.50M | $-54.90M | (m) | 229.57% | 60.39% | (m) | (m) |
| 2022-03-31 | $37.53M | $24.13M | $9.77M | $-42.39M | (m) | 155.52% | 40.47% | (m) | (m) |
| 2021-12-31 | $41.71M | $57.03M | $8.46M | $-12.16M | (m) | 73.14% | 14.83% | (m) | (m) |
| 2021-09-30 | $41.26M | (m) | $6.71M | $-9.19M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $39.04M | (m) | $4.82M | $-3.62M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $33.58M | (m) | $2.20M | $-14.17M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $18.83M | (m) | $839.00K | $-27.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $3.16M | (m) | $18.00K | $-4.30M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |